expressed in the cochlea , encodes for the gap junction protein Connexin 26 (Cx26), whose function is crucial for intercellular communication, particularly in the recycling of potassium ions (K ϩ ) which occurs through a lateral and a medial transcellular pathway. In the lateral route, K ϩ effl uxing from outer hair cells is resorbed by Deiters ' and tectal cells and fl ows via gap junctions through Hensen ' s, Claudius ' and outer sulcus cells to effl ux into stroma. K ϩ subsequently diffuses via gap junctions through type 1 fi brocytes and strial basal and intermediate cells into the intrastrial compartment. In the medial path, the K ϩ released by the inner hair cells travels through inner phalangeal cells, border cells, inner sulcus cells directly or by way of limbal fi brocytes via gap junctions, similar to the spiral ligament, and is fi nally released back into the endolymph via the interdental cells (Spicer & Schulte, 1998) .
Original Article
Distribution and phenotype of GJB2 mutations in 102 Sicilian patients with congenital non syndromic sensorineural hearing loss A decreased synthesis or an altered function of Cx26 may therefore reduce the effi ciency of K ϩ circulation leading to impaired hearing sensitivity (Wangemann, 2002) . Additionally, as evidenced by the c.250G Ͼ C mutation (p.V84L) studied by Beltramello et al (2005) , Cx26 regulates also the permeability to Ca 2 ϩ -mobilizing messenger inositol triphosphate (IP3), allowing a metabolic coupling between connected cells which is necessary to generate an endocochlear potential.
Also, mutations in GJB6 , a gene encoding for Connexin 30 (Cx30), a gap junction protein co-localized in the inner ear with Cx26, can be responsible for NSHL. Particularly, two large deletions in GJB6 have been studied and have often been identifi ed in trans with single GJB2 recessive mutations, suggesting a possible recessive digenic inheritance (Del Castillo et al, 2002 . GJB6 deletions are also linked with hearing impairment in patients who carry one GJB2 recessive mutation in trans, as a result of the abolition of an as-yet-unidentifi ed cisregulatory element responsible for the expression of the GJB2 gene in the inner ear. Common et al (2005) , analysing immunohistochemical data of the sweat glands of an individual compound heterozygous for c.35delG in GJB2 and del( GJB6 -D13D1830) in GJB6 , observed that Cx26 expression was affected by del( GJB6 -D13S1830). The functional effect on Cx26 protein pointed to the disruption of a putative cis-regulatory element which appears to function with cell-type specifi city within the sweat gland. Rodriguez-Paris and Schrijver (2009), studying three unrelated individuals compound heterozygous for a GJB2 mutation and del( GJB6 -D13S1830), demonstrated that the mutated GJB2 allele in trans with del( GJB6 -D13S1830) was expressed, whereas the GJB2 allele located in cis with the deletion was not expressed at all. Also del( GJB6 -D13S1854), similar to del( GJB6 -D13S1830), disrupts human GJB2 expression at the transcriptional level, but, differently from del( GJB6 -D13S1830), it is associated with low residual GJB2 expression (Rodriguez-Paris et al, 2011) .
The c.35delG mutation is by far the most common pathogenic GJB2 allele in Caucasians, (Denoyelle et al, 1997 ) with a carrier frequency among European hearing individuals from 1% to 4% (Kenneson et al, 2002) . A South-North gradient in c.35delG carrier frequency was observed by Gasparini et al (2000) , with an average carrier frequency of 2.8% in Southern Europe, higher than Central and Northern Europe (1.3%). Particularly the Mediterranean region presents the highest c.35delG frequency with Greece representing, as suggested by Lucotte (2007) , the ' geographical center ' of this mutation; in Sicily, which was one of the regions of Ancient Greek colonization, Niceta et al (2007) , studying 1040 newborns who underwent GJB2 gene mutational screening, estimated a c.35delG carrier rate of 2.9%.
The main objective of this work was to study the frequency of GJB2 mutations among Sicilian NSHL patients, trying to correlate the genotype with the severity of hearing impairment. In particular, considering the high prevalence of c.35delG found, we analysed the variability of the degree of deafness between c.35delG homozygotes and c.35delG heterozygotes. We compared also the genetic profi le of our sample with those of other populations of the Mediterranean area to evidence the main differences or similarities.
Materials and Methods

Study sample
We performed a retrospective study of audiological and genetic data that we collected from 102 patients with a variable degree of hearing impairment over recent years at the Audiology Department of the University of Palermo. All the included subjects, aged between 6 and 65 years, were affected by bilateral NSHL and carried at least one GJB2 mutation. Individuals with syndromic, unilateral or acquired hearing impairment were excluded from this study. A detailed history was taken to rule out the presence of environmental causes associated with SNHL (Joint Committee on Infant Hearing, 2007). After Ethical Committee approval, an informed consent was obtained from all participants and from parents of patients younger than 18 years old.
Clinical and audiometric evaluation
All patients underwent a physical examination of the ears through micro-otoscopy; audiometric tests and tympanograms were performed in all subjects studied. Air conduction pure-tone average thresholds at frequencies 0.5 -1 -2 -4 kHz (PTA 0.5 -4 kHz ) were calculated for each ear and were used to classify hearing loss severity. Average thresholds ranging between 21 and 40 dB HL were defi ned as mild hearing loss, 41 -70 dB HL as moderate, 71 -95 as severe hearing loss, and Ͼ 95 dB HL as profound hearing loss, as suggested by Liu et al (2005) . SNHL was classifi ed in ' symmetrical ' when in presence of inter-aural threshold differences Ͻ 30 dB, and ' asymmetrical ' , when inter-aural threshold difference was Ն 30 dB.
Mutation detection
After extracting DNA samples from peripheral blood, all subjects were analysed regarding the basal promoter, exon 1 and the coding region of GJB2.
Genomic DNA was extracted classically from peripheral blood samples with the salting-out method. Molecular analysis of GJB2 gene was performed with PCR and direct sequencing. Exon 1 was amplifi ed with the primers Cx1 forward (5 ′ -TCAAAGGAACTAGGAGATCGG-3 ′ ) and Cx1 reverse (5 ′ -CAAGGACGTGTGTTGGTCCAG-3 ′ ). Exon 2 was amplifi ed with the primers GAP1 forward (5 ′ -CCTAT GACAAAC-TAAGTTGGTTC-3 ′ ) and CONN reverse (5 ′ -GACAGCTGAGCAC GGGTTGCCTC-3 ′ ).
USB ® ExoSAP-IT ® PCR Product Cleanup protocol (37 ° C for 30 minutes and then 95 ° C for 5 minutes) was performed to remove leftover primers and unincorporated dNTPs (Affymetrix, Inc.).
Cleaned up PCR products were sequenced from both ends, using the same primers as used for PCR reactions, with Applied Biosystem (ABI) PRISM ® BigDye ® Terminator v3.1 Cycle Sequencing Kits and analysed with ABI PRISM 3100 DNA automatic sequencer.
Following PCR protocol and using primers described by Del Castillo et al (2005) , the GJB6 gene was also checked to rule out the presence of mutations del( GJB6 -D13S1830) and del( GJB6 -D13S1854). following usual conditions of application. Group data were expressed as percentages and median (95% confi dence intervals).Statistical comparisons between two groups were made using Student ' s paired t-test. Signifi cance was set at 0.05.
Statistical analysis
Results
The study sample comprised 102 NSHL patients, 52 males (50.99%) and 50 females (49.01%) (Sex ratio ϭ 1.04). With a mean age of 13.72 Ϯ 9.75 years (median 11.5 years), the majority of participants (75.49%) were within the range of 6 -17 years. Audiologic evaluation revealed that the 95.1% (97/102) of the total population was affected by symmetric SNHL, whereas the others (4.9%) presented an asymmetric hearing loss. The majority of subjects (96.08%, 98/102) had a stable SNHL and only four persons (3.92%) presented a progressive worsening of hearing.
As shown in Table 1 , all degrees of hearing loss were observed in our population. All subjects studied were positive to GJB2 mutations; no variants in the basal promoter and exon 1 were identifi ed. No anomalies in GJB6 gene were found. Fifteen different mutations in GJB2 were recognized, and seventeen different genotypes were detected in our study sample.
Of the 102 patients of our cohort, 83 (81.37%) harboured at least one c.35delG mutation, 11(10.78%) a c.167delT, and 10 (9.8%) a c.-23 ϩ 1G Ͼ A; c.35delG, c.167delT, and c.-23 ϩ 1G Ͼ A represented respectively the 76.3% (132/173), 6.93% (12/173) and 5.78% (10/173) of all mutated GJB2 alleles. Each remaining mutation observed involved less than 4% of patients.
We classifi ed c.35delG carriers in three subgroups: the fi rst (G 1 ), composed by 49 patients who were homozygous for the c.35delG mutation; the second (G 2 ), and the third (G 3 ) respectively constituted by 15 subjects carrying a c.35delG mutation associated with other GJB2 mutations in trans (c.35delG/ non-c.35delG), and 19 patients with a c.35delG/Wt genotype ( Table 1) .
The study of the audiologic profi le of G 1 group revealed a mean PTA 0.25-4 kHz of 96.79 Ϯ 21.11 dB HL (median ϭ 100 dB HL), with the 53.06% (26/49) of audiograms characterized by a ' fl at loss ' while the 46.94% (23/49) consisted in a ' sky slope' curve; thirty-nine subjects were affected by profound, eight by severe, and two by moderate SNHL (Figure 1) .
Concerning G 2 patients, four different genotypes were recognized (c.35delG/c.-23 ϩ 1G Ͼ A, c.35delG/c.269T Ͼ C, c.35delG/ c.167delT, c.35delG /c.535 G to C) with a mean PTA 0.25-4 kHz of 73.8 Ϯ 27.41 dB HL. A total of 53.33% of subjects (8/15) presented a fl at, 26.66% (4/15) an ' U shaped ' , and 20.01% (3/15) a sloping audiogram; ten patients had a severe to profound hearing impairment, whereas fi ve individuals were affected by mild to moderate SNHL.
From the analysis of the audiologic characteristics of G 3 group it resulted in a mean PTA 0.25-4 kHz of 87.78 Ϯ 26.9 dB HL; the majority of audiograms were represented by sloping curves (47.38%, 9/19), followed by fl at and ' U shaped ' audiograms in 36.84% (7/19) and 15.78% (3/19) of cases respectively; eleven probands were affected by profound, four by severe, three by moderate and only one by mild SNHL.
With a prevalence of 79.59% (39/49), 40% (6/15), and 57.89% (11/19) of profound hearing loss among G 1 , G 2, and G 3 groups, the study of the audiologic phenotype revealed a statistical signifi cant difference between these groups (P ϭ 0.012). Distribution of hearing thresholds (for 0.25 -0.5 -1 -2 -4 kHz) relative to G 1 , G 2, and G 3 groups is reported in Figure 2 . It is well shown that the highest mean PTA 0.25-4 kHz values were associated with c.35delG homozygous genotype, with a statistical signifi cant difference with respect to G 2 group for all frequencies studied (P Ͻ 0.01) and to G 3 limited to 1 -2 -4 kHz frequencies (P Յ 0.05).
The study of a box plot (Figure 2 ) for each group revealed a lower variability in the degree of SNHL among G 1 patients (mean IQR 0.25-4 kHz ϭ 26 dB HL) than among G 2 (mean IQR 0.25-4 kHz ϭ 41.5 dB HL) and G 3 subjects (mean IQR 0.25-4 kHz ϭ 40 dB HL). With a prevalence of 79.59% (39/49), 40% (6/15), and 57.89% (11/19) of hearing loss Ն 90 dB HL for 2 -4 kHz frequencies, it resulted a statistical signifi cant difference between G 1 , G 2, and G 3 (P ϭ 0.012); additionally, concerning 0.25 and 0.5 kHz frequencies, G 2 is associated with a higher variability in the distribution of data and a greater percentage (46.66%, 7/15) of patients affected by mild to moderate hearing loss than G 1 (P ϭ 0.032).
The c.167delT mutation was found in 11 probands (10.78%), associated with four different genotypes: c.167delT homozygous, c.167delT/c.35delG, c.167delT/c.139G Ͼ T, c.167delT/Wt. From the study of the audiologic data of all c.167delT carriers it resulted in a mean PTA 0.25-4 kHz of 90.18 Ϯ 26.49 dB HL and a profound SNHL in the majority of cases (72.72%, 8/11). Particularly, the fi ve subjects with a c.167delT/c.35delG genotype presented a variable degree of hearing loss (one moderate, one severe, and three profound) and a mean PTA 0.25-4 kHz of 86.6 Ϯ 17.76 dB HL, lower than non c.35delG /c.35delG carriers but without any signifi cant difference (P ϭ 0.067).
The c.-23 ϩ 1G Ͼ A mutation was identifi ed in 10 patients (9.8%) and distributed in three genotypes (c.-23 ϩ 1G Ͼ A /c.35delG, c.-23 ϩ 1G Ͼ A /c. 313del14, c.-23 ϩ 1G Ͼ A /Wt; two probands were affected by profound, four by severe, three by moderate, and one by mild SNHL, with a mean PTA 0.25-4 kHz of 67.2 Ϯ 24.8 dB HL, lower than that of c.167delT carriers (P ϭ 0.006).
Discussion
Among more than 90 different GJB2 mutations c.35delG accounts for up to 75% of mutated alleles in populations with European ancestry (Gasparini, 2000; Oguchi et al, 2005) . In the Mediterranean area, with a great diffusion in the general population (carrier frequency of ~ 1/30), c.35delG represents the most common pathological GJB2 allele associated with NSHL (Lucotte et al, 2005) . We evidenced in fact a c.35delG frequency of 76.3% among the total mutated GJB2 alleles (132/173), in line with data relative to Tunisia (85.4%), Spain (82%) Algeria (76%), Turkey (76%), France (69%), Portugal (85%), Morocco (90.8%), and Greece (95.2%) Pampanos et al, 2002; Kalay et al, 2005; Marlin et al, 2005; Abidi et al, 2008; Ammar-Khodja et al, 2009; Chora et al 2010; Rihai et al, 2013) .
It is important to underline that GJB6 mutations, which were not found in our cohort, represent only a small percentage of DFNB1 mutations in our country; in fact, as demonstrated by many studies published previously, GJB6 mutations were not or sporadically recognized in Italian NSHL patients, with an evident difference between Northern and Southern Italy ( 129 hearing-impaired infants from the Campania region, did not evidence any GJB6 mutations; Primignani et al (2009) and Berto et al (2009) instead found GJB6 mutations only in three (0.4%) and fi ve patients (1.3%) of two cohorts from Northern Italy composed respectively by 734 and 385 patients. On the contrary, in other countries of Western Europe such as Portugal and France, higher percentages of these mutations were observed (7.4% and 8.2% respectively) and also in Spain, where the GJB6 mutations represent the second most frequent cause of prelingual deafness (Del Castillo et al, 2003) ; Del Castillo et al (2002) described previously this peculiar geographical distribution of GJB6 mutations, especially of del( GJB6 -D13S1830), for which they suggested a ' common founder ' to justify the greater prevalence in certain populations. In the 48.04% (49/102) of c.35delG homozygotes in our cohort, 95.92% (47/49) had a severe to profound degree of hearing loss and a median PTA 0.5-2 kHz of 100 dB HL, similar to data reported by Hismi (90.9% of severe to profound HL and a median PTA 0.5-2 kHz of 104 dB HL) and Cryns (91.56% of severe to profound HL and a median PTA 0.5-2 kHz of 102 dB HL) (Cryns et al, 2004; Hismi et al, 2006) . Additionally, also from the comparison of our results with those of Iliadou (100% of severe to profound HL and a mean PTA 0.5-2 kHz of 99.78 dB HL) and Santos (100% of severe to profound HL and a mean PTA 0.5-2 kHz of 101.5 dB HL), no signifi cant difference was evidenced with respect to our data (Iliadou et al, 2004; Santos et al, 2005) . However, even if c.35delG/c.35delG was the most represented genotype among the studies cited, a certain variability in its prevalence emerged. Hismi et al (2006) and Cryns et al (2004) , for example, found higher frequencies of this genotype (69.8% and 60% respectively), differently from our work (48.03%, 49/102) and from Iliadou et al (2004) and Santos et al (2005) (25.2% and 47.36% respectively) . This discrepancy could be explained considering that the fi rst two authors cited included in their works only subjects carrying biallelic GJB2 mutations. In fact, by excluding patients carrying only one GJB2 mutation, the c.35delG/c.35delG percentage found in our cohort increases to 69.01% (49/71). Furthermore, it is clear that there is a correlation between this genotype and an audiological phenotype characterized by severe to profound hearing loss, even if, cases of mild to moderate SNHL were previously reported (Wilcox et al, 2000; Snoeckx et al, 2005; Hismi et al, 2006) and were also observed in our sample (2/49 of c.35delG/c.35delG carriers). The presence of different degree of hearing impairment in patients carrying the same GJB2 mutations is not clearly understood, but many authors underlined the role of environmental factors or modifi er genes as potential causes of this variability (Hismi et al, 2006; Hilgert et al, 2009; Picciotti et al, 2009) .
We compared the audiological phenotypes of patients homozygous for c.35delG (G 1 ), c.35delG/non-c.35delG (G 2 ), and c.35delG/ Wt carriers (G 3 ). From this analysis a more severe hearing impairment in G 1 subgroup (P ϭ 0.012) emerged, with a statistical significant difference with respect to G 2 group for all frequencies studied (P Ͻ 0.01) and to G 3 limited to 1 -2 -4 kHz frequencies (P Ͻ 0.05); G 2 instead was characterized by a higher percentage (46.66%, 7/15) of patients affected by mild to moderate hearing loss with respect to G 1 patients (P ϭ 0.032). The study of distribution of PTA 0.25-4 kHz hearing thresholds showed in Figure 2 clearly reveals a close hearing loss spectrum for G 1 patients, with an accumulation of values around 100 -120 dB HL, especially for high frequencies.
Concerning c.167delT, the second most frequent mutation recognized in our cohort (10.78%, 11/102), it was observed associated with c.35delG in the 45.45% (5/11) of cases and was characterized by a moderate to profound hearing loss (mean PTA We found the c.-23 ϩ 1G Ͼ A mutation in the 9.8% (10/102) of our cohort with a mild to profound spectrum of hearing loss; lower percentages were evidenced by Cryns et al (2.89%), Snoeckx et al ( Ͻ 1%), and Berto et al (1.7%) studies (Cryns et al 2005; Snoeckx et al, 2005; Berto et al, 2009 ). These studies identifi ed this mutation mainly in the heterozygous state and associated with c.35delG. From the comparison of the audiological profi le of our c.-23 ϩ 1G Ͼ A /c.35delG patients (median PTA 0.5-4 kHz ϭ 70 dB HL) with literature data, the median hearing threshold seems to be superimposable; in fact Cryns et al (2005) and Snoeckx et al (2005) evidenced respectively median values of 62 dB HL and 64 dB HL among 7 and 16 patients with a c.35delG/ c.-23 ϩ 1G Ͼ A genotype. On the contrary Santos et al (2005) described two cases of profound SNHL associated with c.35delG/ c.-23 ϩ 1G Ͼ A (mean PTA 0.5-2 kHz ϭ 97.9 dB HL); also in our cohort one patient was identifi ed with profound SNHL. All these data seems to be contradictory, refl ecting a variability in the phenotype associated to a single genotype and are not explainable on the basis of functional studies; in fact, D ' andrea et al (2002) and Shanin et al (2002) demonstrated, for c.35delG and c.-23 ϩ 1G Ͼ A, do not yield detectable Cx26 protein and mRNA respectively. This is inconsistent with the observation made by Snoeckx et al (2005) and supported by our data, that c.35delG/ c.-23 ϩ 1G Ͼ A compound heterozygotes had signifi cantly less severe hearing impairment compared to c.35delG homozygotes (P Ͻ 0.0001).
In conclusion, the present study, analysing the genetic profi le of NSHL Sicilian patients, highlights the role of certain GJB2 mutations (c.35delG, c.167delT, c.-23 ϩ 1G Ͼ A) as the most frequent causes of congenital deafness in Sicily. Also from the study of our data, it emerged a real diffi culty to identify precise genotypephenotype correlations, even in cases of certain genotypes (as c.35delG homozygotes) which are mainly associated to a determinate degree of hearing impairment. Future research is necessary to provide additional data that could improve the knowledge about the effects of modifi er genes and environmental factors in the variability of audiologic phenotype.
